Role of parenteral nutrition in cancer patients undergoing high-dose chemotherapy followed by autologous peripheral blood progenitor cell transplantation.
High-dose chemotherapy followed by autologous bone marrow or peripheral blood progenitor cell transplantation represents a recognized option in the treatment of solid tumors and hematologic diseases. Patients receiving high-dose chemotherapy are traditionally supported with parenteral nutrition with the aim to prevent malnutrition secondary to gastrointestinal toxicity and metabolic alterations induced by the conditioning regimens. Nevertheless, well-defined guidelines for its use in this clinical setting are lacking and there are several areas of controversy.
Tartarone
Alfredo
A
Division of Medical Oncology and Hematology,Centro di Riferimento Oncologico della Basilicata (CROB), Rionero in Vulture (PZ), Italy. tarta1@virgilio.it
Wunder
Jenna
J
Romano
Gianpiero
G
Ardito
Raffaele
R
Iodice
Giovanni
G
Mazzuoli
Silvia
S
Barone
Marialucia
M
Matera
Rosella
R
Di Renzo
Nicola
N
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000628:therapy; D009748:Nutrition Disorders / Q000209:etiology / Q000628:therapy; D010288:Parenteral Nutrition; D036102:Peripheral Blood Stem Cell Transplantation; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D014182:Transplantation, Autologous